Here, we showed the first time that IL-8 plasma level in NSCLC patients is correlated with duration of EGFR TKI treatment in NSCLC (Fig. 1d), and IL-8 intervenes in resistance of EGFR TKIs (Figs. 2, 3, and Supplementary Fig. S3). This evidence concerns the gene EGFR and non-small cell lung carcinoma.